A detailed history of China Universal Asset Management Co., Ltd. transactions in Myriad Genetics Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 17,468 shares of MYGN stock, worth $233,372. This represents 0.05% of its overall portfolio holdings.

Number of Shares
17,468
Previous 10,634 64.27%
Holding current value
$233,372
Previous $260,000 83.85%
% of portfolio
0.05%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$23.97 - $28.6 $163,810 - $195,452
6,834 Added 64.27%
17,468 $478,000
Q2 2024

Jul 19, 2024

SELL
$17.98 - $25.47 $118,775 - $168,254
-6,606 Reduced 38.32%
10,634 $260,000
Q1 2024

Apr 29, 2024

BUY
$17.59 - $23.59 $122,901 - $164,823
6,987 Added 68.15%
17,240 $368,000
Q4 2023

May 21, 2024

SELL
$13.91 - $21.32 $97,189 - $148,962
-6,987 Reduced 40.53%
10,253 $196,000
Q4 2023

Jan 23, 2024

BUY
$13.91 - $21.32 $113,394 - $173,800
8,152 Added 388.01%
10,253 $196,000
Q3 2023

May 21, 2024

BUY
$15.99 - $23.22 $16,501 - $23,963
1,032 Added 96.54%
2,101 $33,000
Q3 2023

Oct 30, 2023

BUY
$15.99 - $23.22 $16,501 - $23,963
1,032 Added 96.54%
2,101 $34,000
Q2 2023

May 21, 2024

SELL
$17.56 - $23.76 $509 - $689
-29 Reduced 2.64%
1,069 $24,000
Q2 2023

Jul 27, 2023

SELL
$17.56 - $23.76 $509 - $689
-29 Reduced 2.64%
1,069 $25,000
Q1 2023

May 21, 2024

BUY
$15.26 - $23.75 $4,196 - $6,531
275 Added 33.41%
1,098 $25,000
Q1 2023

Apr 27, 2023

BUY
$15.26 - $23.75 $4,196 - $6,531
275 Added 33.41%
1,098 $26,000
Q4 2022

May 21, 2024

SELL
$14.51 - $20.99 $238,210 - $344,592
-16,417 Reduced 95.23%
823 $11,000
Q4 2022

Jan 31, 2023

BUY
$14.51 - $20.99 $986 - $1,427
68 Added 9.01%
823 $12,000
Q3 2022

Oct 21, 2022

BUY
$18.21 - $27.88 $13,748 - $21,049
755 New
755 $14,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.08B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.